Fidson Healthcare

What Fidson Healthcare does

Fidson Healthcare Plc is a Nigerian pharmaceutical manufacturer founded in 1995 and listed on the Nigerian Exchange (NGX: FIDSON) since 2008. The company operates a single WHO-cGMP compliant manufacturing facility in Sango Ota — described as the largest pharmaceutical facility in Nigeria and Sub-Saharan Africa — with 10 production lines producing over 250 NAFDAC-registered branded products across major therapeutic classes including anti-infectives, cardiovascular, gastrointestinal, antiretroviral, anti-malarial, analgesic, hematinics, and supplements. Its portfolio includes flagship brands Astymin (amino acid/vitamin blend distributed in approximately 40 countries), Fidvite (children's multivitamin), Aventra ProVision (ophthalmics), Cresidox, Gibitor, Ferobin, Neofidrol, and the affordable H.E.L.P tier.

Fidson monetises through prescription (ethical) pharmaceutical sales and OTC/consumer healthcare products distributed via a network of registered distributors, 11 company-owned depots across Nigeria, and a field force of more than 260 medical representatives serving hospitals, clinics, pharmacies, and retail outlets. Ethical drug sales reached N77.8 billion in 2025, with total revenue of N119.06 billion (up 41% year-on-year) and profit before tax of N14.96 billion (up 94% year-on-year). Revenue is naira-denominated and geographically concentrated in Nigeria, with export sales identified as a growth lever into other African markets.

The company employs 501–1,000 staff and is positioned as the largest private employer of pharmacists in Nigeria. Customer segments are healthcare providers and hospitals (primary, business-to-business) and consumers/patients (primary, retail), with international African markets identified as a tertiary segment. Distribution is reinforced by CSR partnerships, public-health engagements, and industry recognition including NHEA Pharmaceutical Manufacturing Company of the Year (2024) and NGX Best Performing Stock in Healthcare (2021). Recent capital actions include a N21 billion rights issue announced in December 2025 to fund a planned joint venture pharmaceutical plant, capex, and debt reduction.

Name

Fidson Healthcare

Legal name

Fidson Healthcare Plc

Website

https://fidson.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Fidson Healthcare Plc is a Nigerian pharmaceutical manufacturer that produces WHO-cGMP compliant branded medicines across major therapeutic classes, distributing them through 11 depots and 260+ medical representatives to hospitals, pharmacies, and consumers across Nigeria and select African export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Ophthalmic Goods (3851)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

akta.pro secondary industries

Multivitamins & Daily Packs (CRADAGAC), OTC & Consumer Health Distributors (HLAIAJAC), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Pharmaceutical manufacturing
• Ethical pharmaceutical products
• Consumer healthcare products
• Ophthalmic preparations
• Nutritional supplements

Headquarters

HQ city

Obanikoro

HQ country

Nigeria

HQ region

Africa

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Ethical Drug Sales: Prescription pharmaceutical products sold through healthcare providers, hospitals, and pharmacies. Includes products across therapeutic classes such as anti-infectives, cardiovascular, gastrointestinal, antiretroviral, anti-malarial, analgesic, and hematinics. In 2025, ethical drug sales reached N77.8 billion representing 41.5% growth.
2. OTC and Consumer Healthcare Products: Over-the-counter products including multivitamins (Fidvite, Fidson Multivitamin syrup), supplements, and consumer healthcare products sold through retail channels and distributors.
3. Export Sales: International sales of pharmaceutical products to other African markets as part of expansion strategy to become the healthcare provider of choice in Africa.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Fidson Healthcare Plc manufactures and distributes a broad portfolio of WHO-cGMP compliant pharmaceutical products across major therapeutic classes including anti-infectives, cardiovascular, gastrointestinal, antiretroviral, anti-malarial, analgesic, and hematinics. The company also markets consumer health brands such as Astymin (amino acid/vitamin supplement), Fidvite (children's multivitamin), Ferobin (blood builder), and the Aventra ProVision ophthalmic range. Products are sold through ethical (prescription) and OTC channels via a network of 11 regional depots, 260+ medical representatives, registered distributors, and retail pharmacies across Nigeria, with growing exports to other African markets.

Product overview

Fidson Healthcare Plc is Nigeria's leading pharmaceutical manufacturing company with a single unified product portfolio centered on WHO-cGMP compliant manufacturing of high-quality pharmaceutical products. The company operates one WHO-cGMP compliant manufacturing facility in Sango Ota with 10 production lines. Their product portfolio spans major therapeutic classes including anti-infectives, gastrointestinal, antiretroviral, anti-malarial, cardiovascular, analgesic, haematinics, and supplements. Key brands include Astymin (amino acids/vitamins), Fidvite (children's multivitamin), Wellness Naturally (natural health), and Aventra ProVision (ophthalmic care including Atropine 1% Eye Drops). The company also offers specialized products like Neofidrol (skin care), Cresidox (cardiovascular), Gibitor (neurological), and Ferobin (hematinic). Their H.E.L.P (Health Essentials at Low Prices) line provides affordable medications for lower-income segments. Distribution is supported by 11 strategically located depots across Nigeria. The company operates as a fully integrated pharmaceutical manufacturer rather than a software platform, with no API or AI-based product offerings.

Differentiator

Problem solved

Functional benefit

Brands

• Fidvite: A multivitamin brand supporting the healthy growth and development of children aged 0-12.
• Wellness Naturally
• Astymin
• Aventra proVision
• Neofidrol
• Cresidox
• Gibitor
• FEROBIN

Products and services

• Pharmaceuticals (Main Portfolio) WHO-cGMP compliant pharmaceutical products across major therapeutic classes including anti-infectives, gastrointestinal, antiretroviral, anti-malarial, cardiovascular, analgesic, haematinics, and supplements, sold through healthcare providers, hospitals and pharmacies.
• Astymin Uniquely formulated blend of amino acids, vitamins and minerals trusted in about 40 countries for promoting mental alertness, physical activity and improved immunity.
• Fidvite Children's multivitamin brand supporting the healthy growth and development of children aged 0-12 years, including Fidvite Multivitamin Syrup.
• Wellness Naturally Brand offering natural solutions for delicate life challenges and general wellness.
• Aventra ProVision Ophthalmic business unit providing targeted eye care solutions across anti-infectives, mixed anti-inflammatory, antibacterial, anti-glaucoma, and anti-allergy treatment ranges.
• Atropine 1% Eye Drops Ophthalmic preparation developed by Aventra proVision for myopia progression control and broader eye care treatment in Africa.
• Cresidox Anti-hypertensive medication (carvedilol 6.25mg and 12.5mg) for slowing progression of heart failure, treating high blood pressure, congestive heart failure, and left ventricular dysfunction.
• Gibitor Anticonvulsant medication (gabapentin 300mg) for treatment of epilepsy, post-herpetic neuralgia, and neuropathic pain.
• Neofidrol Acne Lotion Anti-infective and anti-inflammatory lotion (Neomycin and Methylprednisolone) for managing allergic skin conditions including acne, pimples, and shaving bumps.
• Ferobin Blood builder / hematinic that aids in quick restoration of hemoglobin levels, supporting blood donation advocacy.
• H.E.L.P. (Health Essentials at Low Prices) Products Affordable essential healthcare product line including Fidson Multivitamin syrup, Fidson Paracetamol syrup, Fidson Vitamin B complex syrup, Fidson Vitamin C syrup, Fitulin, Fidvite, and Mist Mag, designed to provide quality affordable healthcare for every socio-economic class.

Quantifiable outcome

• Revenue grew 41% to N119.06 billion in 2025
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, minor and strategic.

• Clinton Health Access InitiativecoreStrategic or Co-development Partner · 22 June 2026Partnership to support Lagos State Government's statewide newborn screening program for Sickle Cell Disease. The program tests every newborn within 48-72 hours after birth using heel-prick tests to enable early detection and immediate preventive care, aiming to reduce childhood deaths from this inherited blood disorder. Nigeria records approximately 150,000 babies born with SCD annually.
• Federal Medical Centre (FMC) AsabaminorStrategic or Co-development Partner · 19 June 2026Fidson donated a fully equipped Theatre Pharmacy to FMC Asaba worth tens of millions of naira as part of its CSR programme. The facility replaces a previously small pharmacy with a larger dedicated unit adjacent to the theatre for easier drug access during emergencies.
• Japanese Firm (TICAD9)strategicStrategic or Co-development Partner · 1 September 2025Fidson signed an MOU with a Japanese firm at TICAD9 (Tokyo International Conference on African Development) for a collaboration aimed at transforming Africa's healthcare landscape. The partnership was signed in September 2025.
• Children Emergency Relief Foundation (CERF)coreStrategic or Co-development PartnerCSR partnership started in 2007 supporting less privileged and vulnerable children in Nigeria through scholarship schemes. Fidson has solidified this partnership over 10 years with consistent scholarship support as part of its CSR focus on education and child welfare.
• Children Development Center (CDC)minorStrategic or Co-development PartnerCSR partnership with Lagos-based facility for children with Down syndrome and Autism Spectrum Disorders. Fidson provides financial donations for infrastructural upgrade and renovation of multisensory classrooms and facilities to support care and development of special needs children.
• Lagos State Blood Transfusion ServicecoreStrategic or Co-development PartnerPartnership for voluntary blood donation advocacy including participation in World Blood Donor Day events. Fidson received recognition from Lagos State Government for its dedication and commitment to blood donation advocacy through its FEROBIN brand.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Emzor Pharmaceutical Industries: One of Nigeria's leading indigenous pharmaceutical manufacturers with a broad portfolio across antibiotics, analgesics, multivitamins, and consumer health products. Direct competitor to Fidson in the Nigerian domestic market across overlapping therapeutic categories and OTC brands.
• May & Baker Nigeria: Long-established Nigerian pharmaceutical manufacturer producing prescription drugs, OTC products, and consumer health brands. Competes directly with Fidson across ethical pharmaceutical categories and shares similar domestic distribution challenges and opportunities.
• Chi Pharmaceuticals: Nigerian pharmaceutical manufacturer with WHO-GMP certified facilities producing generics and branded formulations. Direct competitor in local manufacturing, and Fidson's Head of Factory Operations previously led WHO-GMP certification at Chi Pharmaceuticals.
• Neimeth International Pharmaceuticals: Nigerian pharmaceutical company producing ethical drugs, veterinary products, and consumer health brands. Listed on the NGX like Fidson, making it a comparable investment vehicle and direct competitor in domestic manufacturing.
• Eve Sleep (Julius Berger): Swiss Pharma Nigeria is a local pharmaceutical manufacturer producing generics and branded formulations in the Nigerian market, competing with Fidson across multiple therapeutic categories including antibiotics and supplements.

Broad incumbents

• GlaxoSmithKline (GSK) Nigeria: Multinational pharmaceutical company that has been exiting the Nigerian market, creating supply gaps that Fidson has captured. Historically a major competitor in ethical pharmaceuticals; Fidson has benefited from GSK's retreat from Nigeria.
• Sanofi Nigeria: Global pharmaceutical company with Nigerian operations that has been reducing presence in the market. Fidson has captured share from Sanofi's withdrawal, making Sanofi a benchmark for both Fidson's current opportunity and potential re-entry risk.
• Pfizer Nigeria: Multinational pharmaceutical company with presence in Nigeria, offering ethical pharmaceutical products across multiple therapeutic areas. Represents potential re-entry competitive threat to Fidson as multinationals reassess African strategies.

Regional players

• Aspen Pharmacare: Africa's largest pharmaceutical manufacturer based in South Africa, with regional operations across Sub-Saharan Africa. Comparable to Fidson in scale and category breadth, serving as a benchmark for pan-African expansion strategies.

Others

• Mitsubishi Pharma (Japanese firm via TICAD9): Fidson signed an MOU with a Japanese firm at TICAD9 in September 2025 for collaboration on transforming Africa's healthcare landscape. Represents a strategic partner and potential investor rather than direct competitor, but signals Fidson's positioning within broader pharma supply chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/fidsoncares
• LinkedInlinkedin.com/company/fidson-healthcare-plc
• Instagraminstagram.com/fidsoncares

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fidson Healthcare